YouTube · H1 2026 · 2026-07-27
NVS · NYSE
Novartis AG
Drug Manufacturers - General · Switzerland
USD 160.32-1.8% daily changeQuote 2026-11-11 · USD
- Market cap (USD)
- US$302.78B
- Trailing P/E
- 30.60x
- Forward P/E
- 16.07x
- Quarterly revenue growth
- 4.7%
- Trailing net margin
- 17.5%
- Indicated dividend yield
- 3.0%
Snapshot 2026-11-11 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Company background
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Company websiteQ2 2026
Go beyond the headline.
Novartis Stock (NVS): It Beat Q2 AND Returned to Growth — So Why We Say HOLD
Published 2026-07-21
Comparable businesses
NVS peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | NVSNovartis AGSnapshot 2026-11-11Financial period: 2026-09-30 | AZNAstraZeneca PLCSnapshot 2026-11-11Financial period: 2026-09-30 | MRKMerck & Co., Inc.Snapshot 2026-11-11Financial period: 2026-09-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$302.78B | US$287.66B | US$362.83B | US$325.25Bn=2 |
| Forward P/EProvider forward earnings estimate | 16.07x | 16.39x | 16.39x | 16.39xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 14.46x | 14.85x | 13.88x | 14.36xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 4.7% | 6.7% | 4.7% | 5.7%n=2 |
| Operating marginLatest reported quarter | 34.0% | 25.8% | 35.2% | 30.5%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 3.7% | 2.0% | 3.9% | 2.9%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 1.64x | 1.23x | 1.50x | 1.36xn=2 |
| Debt / equityTotal debt / positive book equity | 1.29x | 0.66x | 1.20x | 0.93xn=2 |
| Trailing P/ETrailing twelve-month earnings | 30.60x | 26.23x | 148.67x | 87.45xn=2 |
| Price / bookPrice / positive book equity per share | 8.13x | 5.56x | 8.09x | 6.82xn=2 |
| EV / salesEnterprise value / trailing revenue | 6.07x | 5.06x | 6.07x | 5.57xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -68.8% | 23.5% | -12.0% | 5.8%n=2 |
| Gross marginTrailing twelve months | 75.2% | 81.8% | 75.2% | 78.5%n=2 |
| Net marginTrailing twelve months | 17.5% | 17.7% | 3.6% | 10.7%n=2 |
| Return on equityProvider trailing return; positive equity only | 24.3% | 22.6% | 5.1% | 13.8%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 19.6% | 9.0% | 20.8% | 14.9%n=2 |
| Dividend yieldIndicated annual dividend / price | 3.0% | 1.7% | 2.3% | 2.0%n=2 |
| Earnings payoutProvider trailing dividend payout | 90.5% | 45.4% | 343.4% | 194.4%n=2 |
| Current ratioCurrent assets / current liabilities | 0.88x | 1.01x | 1.35x | 1.18xn=2 |
| BetaProvider historical market sensitivity | 0.45 | 0.15 | 0.12 | 0.14n=2 |
YouTube · H1 2026 · 2026-07-27
YouTube · Q1 2026 · 2026-05-01
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for NVS
Q2 20262026-07-21
Novartis Stock (NVS): It Beat Q2 AND Returned to Growth — So Why We Say HOLD
Presentation · 2026-07-21 · YouTube